Assistant Professor of Medicine, Harvard Medical School Director of Clinical Research, Leukemia Program, Massachusetts General Hospital
Oncology
Dr. Amir T. Fathi, MD
|
|
Give Review
Amir T. Fathi, MD practices Oncology. He attended Yale University School of Medicine. Yale University School of Medicine is a top medical college. Yale University School of Medicine is ranked 7/57 in Research/PrimaryCare. He received awards:"Meaningful Use Stage 1 Certification". Amir Fathi is also published. He has 38 publications published. The lastest publication: "Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.' He is registered with Medicare.
Publications
- Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
- Myelodysplastic syndromes, version 2.2015.
- Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloi...
- Presentation and outcomes among patients with isolated myeloid sarcoma: a Surveillance, Epidemiology, and End Results database analysis.
- Chromosome 17p deletion in a case of T-cell acute lymphoblastic lymphoma.
- Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia.
- The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond.
- Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: A SEER database analysis.
- Isocitrate Dehydrogenase 1 (IDH1) Mutation in Breast Adenocarcinoma Is Associated With Elevated Levels of Serum and Urine 2-Hydroxyglutarate.
- D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice.
- Treatment of Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation.
- Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues.
- Chronic myelogenous leukemia, version 1.2014.
- Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
- CD30: a new target for ALL?
- The evolving landscape in the therapy of acute myeloid leukemia.
- FLT3 inhibitor-induced neutrophilic dermatosis.
- AML1-ETO mediates hematopoietic self-renewal and leukemogenesis through a COX/β-catenin signaling pathway.
- A unique PML-RARα rearrangement involving chromosomes 11, 15, and 17 in a patient with acute promyelocytic leukemia.
- Trends in all-cause mortality among patients with chronic myeloid leukemia: A Surveillance, Epidemiology, and End Results database analysis.
- Association between baseline body mass index (BMI) and overall survival among patients over age 60 with acute myeloid leukemia (AML).
- Pure erythroid leukemia evolving from a therapy-related myelodysplastic syndrome secondary to treatment for chronic lymphocytic leukemia.
- Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia.
- Infectious pathogens and hematologic malignancy.
- Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy.
- Chronic myelogenous leukemia. Clinical practice guidelines in oncology.
- Molecular alterations underlying eosinophilic and mast cell malignancies.
- Hypereosinophilia in relapsed acute myeloid leukaemia.
- A potential therapeutic target for FLT3-ITD AML: PIM1 kinase.
- FLT3 Inhibition as Therapy in Acute Myeloid Leukemia: A Record of Trials and Tribulations.
- New agents in acute myeloid leukemia: beyond cytarabine and anthracyclines.
- Chemotherapy for advanced stage non-small cell lung cancer.
- Exploiting cellular pathways to develop new treatment strategies for AML.
- Lestaurtinib: a multi-targeted FLT3 inhibitor.
- FLT3 inhibitors: a story of the old and the new.
- New Molecular Abnormalities and Clonal Architecture in AML: From Reciprocal Translocations to Whole-Genome Sequencing.
- Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.
Doctors Specialties
- Internal Medicine
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- BlueConnect HMO
- Blue with Managed Care Behavioral Health HMO
- Preferred Blue PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- Harvard Pilgrim Health Care PPO
- Choice Care PPO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Network Health
- Tufts PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
Awards
- Meaningful Use Stage 1 Certification
Education
-
Harvard School of Public Health -
Johns Hopkins University -
Massachusetts General Hospital -
Yale University School of Medicine
Hospital
-
Massachusetts General Hospital
Helpful Reviews
Similar Doctors
|
|
Dr. Steven M. Corsello, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kerry L. Massman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Julia H. Hayes, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew J. Yee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sridhar Ramaswamy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeremy M. Robbins, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kunal P. Patel, MD |
|
|
Dr. Daniel A. Platt, MD |
|
|
Dr. Kristi J. Larned, MD |
|
|
Dr. Julien L. Pham, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Samuel O. Thier, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Melissa D. Dipetrillo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Navin K. Yadlapalli, MD
This Doctor is OpenDoctor Recommended.
|